HoneyLab, the New Zealand company running the world’s largest research programme into the medicinal uses of honey and other bee products, has appointed two independent directors to its board.
Co-founder and managing director Laurence Greig says that at this stage of the company’s growth the appointment of Dr Ian Boddy and Dr Robert Feldman from 1 August will strengthen the company’s focus on commercialisation through licensing.
Dr Ian Boddy, who has a PhD in organic chemistry, was a Research Fellow at Cambridge University and a Senior Research Leader with the large German agrochemicals company, Schering AG. He is also well-known for his time with the New Zealand Crown Research Institute AgResearch as GM Commercial.
Dr Boddy says, “I’m excited about the opportunity in being involved with HoneyLab. HoneyLab is developing New Zealand honey into global business opportunities and I look forward to working with the board to help achieve that.”
Dr Rob Feldman has a combination of business, medical and research experience spanning two decades. A qualified medical practitioner, he obtained his medical degree in London and his PhD in The Netherlands. He has worked at Harvard Medical School, and has held clinical and academic positions at Imperial College, London.
Dr Feldman comments, “With the company’s clearly differentiated, clinically tested products and a skilled and knowledgeable management team, I believe there is huge potential for HoneyLab. I look forward to being a member of HoneyLab’s team.”
Dr Boddy replaces former chair Paul Morgan who steps down after three years. Mr Greig acknowledges the invaluable contribution made by Mr Morgan saying, “Paul brought a level of robustness and structure to our governance that we might not have considered important as a small company. This gave HoneyLab significant credibility that allowed the company to be taken seriously by overseas pharmaceutical companies as we looked to develop HoneyLab’s licensing opportunities.”